Page 2 - பாண்டியன் சிகிச்சை இன்க் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Selexis SA: Selexis Enters Service Agreement with Pandion Therapeutics to Advance Pandion Antibody Pandion will leverage Selexis proprietary technology platform to advance an antibody targeting autoimmune and inflammatory diseases Selexis SA, a JSR Life Sciences company, announced today that it has signed a service agreement with Pandion Therapeutics, Inc., to advance the development of Pandion s PT627, a systemically-acting PD-1 agonist antibody for the potential treatment of autoimmune and inflammatory diseases. Under the terms of the agreement, Pandion will utilize Selexis proprietary SURE technology Platform to rapidly develop the research cell banks (RCBs) necessary to advance PT627 to human trials. Pandion s selection of Selexis as a cell line development partner is a testament to the value of our SURE

Nathan higginson scottRobert meisterYemi onakunleMike beyerPandion therapeutics incXlife sciences companySam brown incCompany inquiries for selexisCorporate communicationsLife sciencesPandion therapeuticsTherapeutic autoimmuneSciences companyநாதன் ஹிக்கின்சன் ஸ்காட்ராபர்ட் மைஸ்டர்மைக் பேயர்